GLRB

Glycine receptor subunit beta (Glycine recept · P48167 · GLRB on Sugi Atlas →

3,772 patent compounds predicted against GLRB, 2,158 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Strychnine (SCHEMBL6272549)	0.66	18/20
Azacosterol (SCHEMBL3176220)	0.56	17/20
SCHEMBL4654859	1.00	15/20
Strychnine (SCHEMBL1330259)	0.87	15/20
Strychnine (SCHEMBL2169884)	0.81	15/20
SCHEMBL3373354	0.79	15/20
SCHEMBL4654862	0.77	15/20
SCHEMBL6425411	0.69	15/20
SCHEMBL3904257	0.68	15/20
SCHEMBL1753345	0.61	15/20
Icajine (SCHEMBL1445138)	0.58	15/20
Brucine (SCHEMBL1748414)	0.54	15/20
Brucine (SCHEMBL1748435)	0.54	15/20
Strychnine (SCHEMBL578374)	0.93	14/20
Strychnine (SCHEMBL578475)	0.90	14/20
Strychnine (SCHEMBL1049901)	0.90	14/20
Strychnine (SCHEMBL1049902)	0.90	14/20
Brucine (SCHEMBL113229)	0.73	14/20
Brucine (SCHEMBL1648976)	0.73	14/20
Brucine (SCHEMBL524833)	0.72	14/20

Clinical trials — most relevant to GLRB by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effects of Levetiracetam on Alcohol Dependent Subjects	PHASE4	COMPLETED
Pain and Chronic Pancreatitis - Clinical End Experimental Studies	PHASE2/PHASE3	COMPLETED
Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers	PHASE3	COMPLETED
Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia	PHASE2/PHASE3	COMPLETED
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD	PHASE3	COMPLETED
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure	PHASE2	UNKNOWN
Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia	PHASE2	COMPLETED
Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia	PHASE2	COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203	PHASE1	COMPLETED
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer	PHASE1	WITHDRAWN
Excitatory Amino Acids and Activated Microglia After Traumatic Brain Injury: a (R)-[11C]PK11195 PET Study	PHASE1	UNKNOWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms	nan	COMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
L-arginine add-on Therapy in Patients With Schizophrenia	nan	COMPLETED
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Potential Synergistic Effect of Combined Blood Flow Restriction Training and Betaine Supplementation on Skeletal Muscle	nan	COMPLETED
Association of Brain Derived Neurotrophic Factor (BDNF) rs6265 Gene Polymorphism With Susceptibility to Epilepsy	nan	UNKNOWN
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting	nan	UNKNOWN
Brain Receptors in Sympathetic Nervous System Regulation	nan	COMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
Protocol Assessment of Motor Cortex rTMS for Treating Neuropathic Pain	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a GLRB binder may also engage these)

Protein	Name	Similarity
P48168	—	1.000	P48168 →
Q9GJS9	—	1.000	Q9GJS9 →
P20781	—	1.000	P20781 →
Q9GQ00	—	0.997	Q9GQ00 →
G5EBR3	—	0.994	G5EBR3 →
P17644	—	0.992	P17644 →
Q18812	—	0.989	Q18812 →
P41849	—	0.989	P41849 →
GABRP	Gamma-aminobutyric acid receptor subunit pi (	0.989	landscape →
GLRA1	Glycine receptor subunit alpha-1	0.988	landscape →
Q09453	—	0.988	Q09453 →
Q95Y52	—	0.988	Q95Y52 →
Q8QZW7	—	0.988	Q8QZW7 →
Q21005	—	0.987	Q21005 →
O16926	—	0.987	O16926 →
Q60S81	—	0.986	Q60S81 →
Q5EA06	—	0.986	Q5EA06 →
Q75NA5	—	0.986	Q75NA5 →
P23414	—	0.985	P23414 →
Q64018	—	0.985	Q64018 →
Q9U358	—	0.985	Q9U358 →
P48181	—	0.984	P48181 →
P22933	—	0.984	P22933 →
Q9U298	—	0.984	Q9U298 →
P49581	—	0.984	P49581 →
P09478	—	0.984	P09478 →
GLRA2	Glycine receptor subunit alpha-2	0.984	landscape →
P07727	—	0.984	P07727 →
P57695	—	0.983	P57695 →
G5ECT0	—	0.983	G5ECT0 →